Aphton Announces Presentation at UBS Global Life Sciences Conference

Aphton Corporation (NASDAQ:APHT), a biotechnology
company focused on the development of immunotherapies for the
treatment of cancer, announced today that Patrick Mooney, M.D.,
Chairman and CEO, will present an overview of the company at the
upcoming UBS Global Life Sciences Conference to be held at the Grand
Hyatt in New York City.
   Dr. Mooney's presentation will be on Tuesday, September 27th at
3:30 p.m. EDT. A live audio webcast of the presentation can be
accessed by visiting the UBS conference website at www.ibb.ubs.com. A
replay of the presentation will begin 3 hours after the actual
presentation and will be available until October 29, 2005.

   About Aphton

   Aphton Corporation, headquartered in Philadelphia, Pennsylvania is
a clinical stage biopharmaceutical company focused on developing
targeted immunotherapies for cancer. Aphton's products seek to empower
the body's own immune system to fight disease. Through the acquisition
of Igeneon AG in March 2005, Aphton acquired late-stage products,
IGN101, a cancer vaccine designed to induce an immune response against
EpCAM positive tumor cells, and IGN311, a fully humanized antibody
against the Lewis Y antigen. Aphton has strategic alliances with Xoma
for treating gastrointestinal and other gastrin-sensitive cancers
using anti-gastrin monoclonal and other antibodies; Daiichi Pure
Chemicals for the development, manufacturing and commercialization of
gastrin-related diagnostic kits; and sanofi-aventis for the
development and commercialization of Insegia (G17DT immunogen) related
to cancers of the gastrointestinal system and other cancers in North
America and Europe. Aphton is also currently seeking other partners
that will support the further development of Insegia. For more
information about Aphton or its programs please visit Aphton's website
at www.aphton.com.